Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors
Abstract
The evolution of amyloid PET in Alzheimer's disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET's trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.
Fields of Study & Subjects
Medical Imaging Techniques and Applications
Glioma Diagnosis and Treatment
Neuroendocrine Tumor Research Advances
Publication details
- Journal / source
- Neuro-Oncology Advances
- Volume
- 8
- Issue
- 1
- Pages
- vdag043–vdag043
- Publication date
- 1 January 2026
- Language
- EN